Cara Therapeutics announced the discontinuation of their clinical program for oral difelikefalin in treating notalgia paresthetica due to lack of clinical benefit.
AI Assistant
TVARDI THERAPEUTICS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.